Efficacy against (%) | Infection (95% CI) | Symptomatic infection (95% CI) | Severe disease (95% CI) | |||
---|---|---|---|---|---|---|
Variant | 14 d after dose 1 | 7 d after dose 2 | 14 d after dose 1 | 7 d after dose 2 | 14 d after dose 1 | 7 d after dose 2 |
Original | 61 (31—79) | 93.3 (85.7—97.4) | 92.1 (68.8—99.1) | 94.1 (89.3—96.8) | 92.1 (68.8—99.1) | 100 |
Alpha | 54.7 (44.8—62.9) | 86 (81—90.6) | 88.1 (83.7—91.5) | 91 (84—95) | 81.6 (71.0—88.8) | 95.7 (73.4—99.9) |